JP2022517415A5 - - Google Patents
Info
- Publication number
- JP2022517415A5 JP2022517415A5 JP2021541234A JP2021541234A JP2022517415A5 JP 2022517415 A5 JP2022517415 A5 JP 2022517415A5 JP 2021541234 A JP2021541234 A JP 2021541234A JP 2021541234 A JP2021541234 A JP 2021541234A JP 2022517415 A5 JP2022517415 A5 JP 2022517415A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- inhibitor
- clause
- checkpoint pathway
- monoclonal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792996P | 2019-01-16 | 2019-01-16 | |
| US62/792,996 | 2019-01-16 | ||
| PCT/US2020/013817 WO2020150434A1 (en) | 2019-01-16 | 2020-01-16 | Methods of inducing an anti-cancer immune response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517415A JP2022517415A (ja) | 2022-03-08 |
| JP2022517415A5 true JP2022517415A5 (https=) | 2023-01-25 |
| JP7693206B2 JP7693206B2 (ja) | 2025-06-17 |
Family
ID=71613420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541234A Active JP7693206B2 (ja) | 2019-01-16 | 2020-01-16 | 抗癌免疫応答を誘導する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220062250A1 (https=) |
| EP (1) | EP3911681A4 (https=) |
| JP (1) | JP7693206B2 (https=) |
| KR (1) | KR20210118101A (https=) |
| CN (1) | CN113574068B (https=) |
| AU (1) | AU2020208414A1 (https=) |
| BR (1) | BR112021013952A2 (https=) |
| CA (1) | CA3126818A1 (https=) |
| IL (1) | IL284695A (https=) |
| MX (1) | MX2021008591A (https=) |
| WO (1) | WO2020150434A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220160692A1 (en) * | 2019-04-09 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer |
| CA3202416A1 (en) * | 2020-12-16 | 2022-06-23 | Pieter Fokko VAN LOO | Multispecific antibodies for the treatment of cancer |
| CN116217468A (zh) * | 2023-02-22 | 2023-06-06 | 天津民祥药业有限公司 | 一种奥帕尼布的新型合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2528451T3 (es) * | 2005-06-17 | 2015-02-10 | Apogee Biothechnology Corporation | Inhibidores de esfingosina cinasa |
| WO2008028968A2 (en) * | 2006-09-08 | 2008-03-13 | Institut Gustave Roussy | Compounds regulating calreticulin, kdel receptor and/or erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment |
| EP2384118A4 (en) * | 2008-12-30 | 2012-01-11 | Musc Found For Res Dev | SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE |
| WO2017060771A2 (en) * | 2015-10-06 | 2017-04-13 | Redhill Biopharma Ltd. | Combination therapies for treating cancer |
| JP6902040B2 (ja) | 2016-01-28 | 2021-07-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 免疫チェックポイント阻害剤の効力を増強する方法 |
| CA3061201A1 (en) * | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
-
2020
- 2020-01-16 US US17/422,647 patent/US20220062250A1/en active Pending
- 2020-01-16 JP JP2021541234A patent/JP7693206B2/ja active Active
- 2020-01-16 AU AU2020208414A patent/AU2020208414A1/en active Pending
- 2020-01-16 BR BR112021013952A patent/BR112021013952A2/pt unknown
- 2020-01-16 MX MX2021008591A patent/MX2021008591A/es unknown
- 2020-01-16 CN CN202080013805.3A patent/CN113574068B/zh active Active
- 2020-01-16 KR KR1020217025449A patent/KR20210118101A/ko not_active Ceased
- 2020-01-16 CA CA3126818A patent/CA3126818A1/en active Pending
- 2020-01-16 EP EP20741946.6A patent/EP3911681A4/en active Pending
- 2020-01-16 WO PCT/US2020/013817 patent/WO2020150434A1/en not_active Ceased
-
2021
- 2021-07-07 IL IL284695A patent/IL284695A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7467527B2 (ja) | 慢性免疫病に対する免疫治療のためのｔｉｍ－３およびｐｄ－１に対する二重特異性抗体 | |
| US11407823B2 (en) | Treatment of cancer with anti-LAP monoclonal antibodies | |
| US20220184012A1 (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| CA2887528C (en) | Enhancement of the immune response | |
| JP2021515566A5 (https=) | ||
| JP2021516976A5 (https=) | ||
| JP2019529418A (ja) | 抗体およびチェックポイント阻害剤の併用療法 | |
| van de Donk et al. | T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA | |
| JP2022517415A5 (https=) | ||
| JP2021522211A (ja) | Ｅｐ４阻害剤およびその使用 | |
| JP2022518232A5 (https=) | ||
| RS63238B1 (sr) | Kombinovana terapija sa anti-cd19 antitelom i azotnim senfom | |
| JP2024504260A5 (https=) | ||
| CN112351795A (zh) | 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法 | |
| WO2015164364A2 (en) | Methods to manipulate alpha-fetoprotein (afp) | |
| CN113574068B (zh) | 诱导抗癌免疫应答的方法 | |
| JP7492752B2 (ja) | 免疫療法のためのアジュバントとしてのグアナベンズ | |
| BR112020025504A2 (pt) | Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido | |
| RU2022129376A (ru) | Комбинированный лекарственный препарат для лечения рака почек |